Evidence map›Paper›PMID 39827219›Full record

ArticleMolecular psychiatry2025

Novel synaptic markers predict early tau pathology and cognitive deficit in an asymptomatic population at risk of Alzheimer's disease.

Jiarui Ao, Cynthia Picard, Daniel Auld, Henrik Zetterberg, Ann Brinkmalm, Kaj Blennow, Sylvia Villeneuve, John C S Breitner, Judes Poirier, PREVENT-AD research group

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Genetic and molecular evidence linking CTSH to Alzheimer's disease pathophysiology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiarui AoDouglas Mental Health University Institute, Montréal, QC, Canada.ORCID 0009-0000-2567-2768
Cynthia PicardDouglas Mental Health University Institute, Montréal, QC, Canada.ORCID 0000-0003-1107-6839
Daniel AuldVictor Phillip Dahdaleh Institute of Genomic Medicine at McGill University, Montréal, QC, Canada.ORCID 0000-0002-9486-1105
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-3930-4354
Ann BrinkmalmClinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden.
Kaj BlennowClinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden.ORCID 0000-0002-1890-4193
Sylvia VilleneuveDouglas Mental Health University Institute, Montréal, QC, Canada.
John C S BreitnerDouglas Mental Health University Institute, Montréal, QC, Canada.
Judes PoirierDouglas Mental Health University Institute, Montréal, QC, Canada. judes.poirier@mcgill.ca.ORCID 0000-0002-8018-4545
PREVENT-AD research group

Funding

Alzheimer's Association #ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-CAlzheimer's Association SG-23-1038904 QCAlzheimer's Drug Discovery Foundation (ADDF) #201809-2016862Fonds de Recherche du Québec - Santé (Fonds de la recherche en sante du Quebec) FRQ-356162Forskningsrådet om Hälsa, Arbetsliv och Välfärd (Swedish Research Council for Health, Working Life and Welfare) #2017-00915 and #2022-00732Forskningsrådet om Hälsa, Arbetsliv och Välfärd (Swedish Research Council for Health, Working Life and Welfare) #2023-00356; #2022-01018 and #2019-02397Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) # PJT 153287, 178210Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT: 178385, 438655Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) RGPIN-2020-04702Hjärnfonden (Swedish Brain Foundation) #FO2017-0243 and #ALZ2022-0006
6 · The paper itself

Abstract

Cognitive dysfunction in Alzheimer's disease (AD) correlates closely with pathology in the neuronal microtubule-associated protein tau. Tau pathology may spread via neural synapses. In a population of cognitively unimpaired elderly at elevated risk of AD, we investigated four cerebrospinal (CSF) markers of synaptic dysfunction and degeneration. Three of these (SYT1, SNAP25, and ADAM23) are derived from pre-synaptic structures, while ADAM22 reflects post-synaptic changes. All four markers correlated strongly with tau protein measures. In statistical models, SYT1 accounted for more than half the total variance in both total- and P(181)-tau levels. Observed correlations with CSF levels of Alzheimer amyloid-β (Aβ42) were somewhat weaker. In longitudinal data, baseline levels of ADAM22 and ADAM23 robustly predicted increase over time in both total- and P-tau. CSF SYT1 levels also correlated with PET image uptake of tau and (at a trend level) Aβ in areas of interest for early AD pathology. CSF SYT1 and SNAP25 levels correlated inversely with a global psychometric score and several of its domain subscales. In quantitative trait loci analyses, all four synaptic markers were associated with at least one AD genetic risk locus. Upon "staging" participants by their evidence of amyloid and tau pathology (A/T/N framework), the CSF synaptic markers were unexpectedly reduced in participants with CSF evidence of amyloid but not tau pathology. They were clearly elevated, however, in the CSF of persons with indications of both tau and amyloid pathology. These observations provide evidence for clear pre-synaptic degeneration in cognitively unimpaired persons with biomarker evidence of early AD pathology.

Indexed as

Alzheimer DiseaseCognition DisordersSynapsestau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedPeptide FragmentsPositron-Emission TomographySynaptosomal-Associated Protein 25Amyloid beta-PeptidesBiomarkersPeptide FragmentsSNAP25 protein, humanSynaptosomal-Associated Protein 25Synaptotagmin Itau Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.